LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Becton Dickinson and Co

Aperta

SettoreSettore sanitario

174.82 1.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

170.98

Massimo

175.54

Metriche Chiave

By Trading Economics

Entrata

27M

330M

Vendite

104M

5.3B

P/E

Media del settore

33.915

56.602

EPS

3.35

Rendimento da dividendi

2.49

Margine di Profitto

6.259

Dipendenti

70,000

EBITDA

93M

546M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+19.81% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.49%

2.45%

Utili prossimi

7 ago 2025

Prossima data del Dividendo

30 giu 2025

Prossima data del' Ex Dividendo

9 giu 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-15B

50B

Apertura precedente

173.3

Chiusura precedente

174.82

Notizie sul Sentiment di mercato

By Acuity

29%

71%

73 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Becton Dickinson and Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2025, 11:18 UTC

Utili

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

5 feb 2025, 22:09 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 nov 2024, 12:59 UTC

Utili

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 nov 2024, 12:56 UTC

Utili

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 mag 2025, 10:33 UTC

Utili

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 mag 2025, 10:33 UTC

Utili

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 mag 2025, 10:32 UTC

Utili

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 mag 2025, 10:32 UTC

Utili

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 mag 2025, 10:31 UTC

Utili

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 mag 2025, 10:31 UTC

Utili

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

1 mag 2025, 10:30 UTC

Utili

Becton Dickinson Updates full-Yr Fiscal 2025 Guidance and Provides Estimated Tariff Impact >BDX

1 mag 2025, 10:30 UTC

Utili

Becton Dickinson Sees FY Adj EPS $14.06-Adj EPS $14.34 >BDX

1 mag 2025, 10:30 UTC

Utili

Becton Dickinson 2Q Net $308M >BDX

1 mag 2025, 10:30 UTC

Utili

Becton Dickinson 2Q EPS $1.07 >BDX

1 mag 2025, 10:30 UTC

Utili

Becton Dickinson 2Q Adj EPS $3.35 >BDX

1 mag 2025, 10:30 UTC

Utili

Becton Dickinson 2Q Rev $5.3B >BDX

5 feb 2025, 21:56 UTC

Utili

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 feb 2025, 21:54 UTC

Utili

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 feb 2025, 21:54 UTC

Utili

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 feb 2025, 21:53 UTC

Utili

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 feb 2025, 21:30 UTC

Utili

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 feb 2025, 21:30 UTC

Utili

Becton Dickinson 1Q Rev $5.2B >BDX

5 feb 2025, 21:30 UTC

Utili

Becton Dickinson 1Q Net $303M >BDX

5 feb 2025, 21:30 UTC

Utili

Becton Dickinson 1Q EPS $1.04 >BDX

7 nov 2024, 11:36 UTC

Utili

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 nov 2024, 11:35 UTC

Utili

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 nov 2024, 11:30 UTC

Utili

Becton Dickinson 4Q EPS $1.45 >BDX

7 nov 2024, 11:30 UTC

Utili

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 nov 2024, 11:30 UTC

Utili

Becton Dickinson 4Q Rev $5.4B >BDX

7 nov 2024, 11:30 UTC

Utili

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

Confronto tra pari

Modifica del prezzo

Becton Dickinson and Co Previsione

Obiettivo di Prezzo

By TipRanks

19.81% in crescita

Previsioni per 12 mesi

Media 206.4 USD  19.81%

Alto 261 USD

Basso 172 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Becton Dickinson and Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

4

Acquista

8

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

167 / 206.99Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

73 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.